OpGen: Encouraging top-line data from Unyvero urinary tract infection (UTI) panel

OpGen: Encouraging top-line data from Unyvero urinary tract infection (UTI) panel

Associated equity: OpGen

OpGen is focused on revolutionising the identification and treatment of bacterial infections. Following the merger with Curetis, it has technology to detect pathogens and predict resistance. Importantly, the AMR Gene Panel and Unyvero platforms have the ability to provide results in hours instead of days.

OpGen — 5 videos in collection

OpGen (Nasdaq CM: OPGN) has announced encouraging top-line data from its Unyvero urinary tract infection (UTI) panel trial.

The Unyvero UTI panel is a diagnostic test designed to detect pathogens and antimicrobial resistance markers related to UTI from native urine specimens without the need for culturing, bringing test times down to less than five hours.

In this video, Edison Group Managing Director, Soo Romanoff and OpGen’s CEO, Oliver Schacht, discuss the significance of the trial data and OpGen’s future plans.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free